Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
about
Clinical and Neurobiological Relevance of Current Animal Models of Autism Spectrum Disorders.The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring.Suramin inhibits Hsp104 ATPase and disaggregase activityMaternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates.Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.Allergic fetal priming leads to developmental, behavioral and neurobiological changes in miceAdvanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders.Ketogenic diet improves behaviors in a maternal immune activation model of autism spectrum disorder.DOCLASP - Docking ligands to target proteins using spatial and electrostatic congruence extracted from a known holoenzyme and applying simple geometrical transformations.Olfactory stem cells reveal MOCOS as a new player in autism spectrum disorders.Epigenetic findings in autism: new perspectives for therapy.Purinergic signaling and energy homeostasis in psychiatric disordersMetabolic Dysfunction Underlying Autism Spectrum Disorder and Potential Treatment Approaches.Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder.An n=1 case report of a child with autism improving on antibiotics and a father's quest to understand what it may mean.Isolated Mitochondria Transfer Improves Neuronal Differentiation of Schizophrenia-Derived Induced Pluripotent Stem Cells and Rescues Deficits in a Rat Model of the Disorder.Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic Poly(I:C).Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial.Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism.The placental interleukin-6 signaling controls fetal brain development and behavior.Nicotine withdrawal-induced inattention is absent in alpha7 nAChR knockout mice.Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases.Fragile X Mental Retardation Protein Restricts Small Dye Iontophoresis Entry into Central Neurons.Animal models for autism in 2017 and the consequential implications to drug discovery.Purinergic system in psychiatric diseases.Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.P2Y1 Receptors - Properties and Functional Activities.Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options
P2860
Q26748761-20EFD852-EED4-4B0A-AAE5-85584D6542C2Q27331695-C5BA9979-D43F-42C3-99B3-9D1BC013AC3EQ28543672-2D1E87CA-F7F6-44E9-8621-AA186AAEAF92Q30238718-B905E0FB-2AD7-45A4-B2E5-EC6CB64321C2Q30418368-448A92F8-C634-4C39-8388-1AFCE3625D24Q30582584-E9A2D686-26BB-48C8-A0DD-27BD04F90ACBQ30654001-9EE4C178-0641-4B83-8A1C-0349EE9955F3Q33618938-AC18B8F4-06E8-42F2-B195-29CA0D7F66A0Q33945211-B118DF3A-17BF-4BB4-AA5E-4BBCBB88486CQ36271744-B7DB5F6D-1FA1-4FAD-86E8-2FC77338DE47Q37069251-5014609C-900E-46D4-80CB-447B0C59938DQ37199039-40976DE3-E5A9-4BC1-9C00-22C347C52949Q37237028-66F35CF2-09BB-42C4-9DB0-FB1CD3A96B89Q37284060-9BB19A30-246B-4CAC-AD94-209C3980010DQ37653680-D871BB19-45A9-4177-8B10-C802D846AD11Q38404704-4C08AEB7-9710-48CE-B591-7AF0642AE858Q39025332-DC8F0E09-65F6-400A-B757-8595537E5089Q40170953-5959766E-70A9-47CE-A9C5-6B57F5514C01Q40800323-3D9BA19F-99B6-4A06-A123-E8C2C20865F1Q40962449-3E8E5E65-76A9-4C33-BE91-19BF0C1F607CQ42363874-6A414466-1955-4852-852B-DE10378D5FBAQ44990351-9CCC2EB4-3106-43FB-8A79-42AFB355F432Q46829706-60D0C76B-F335-484B-87BA-C2EB3924605EQ47551317-74F5AEC4-225B-4A0D-8A71-E15B56ADEA1AQ47626153-AD47702A-0DFE-4F06-B166-570B4A7108BAQ47668964-0A43F616-02D3-4659-A742-021D530FEE6EQ47758170-2F71E74E-F25A-425F-BFE8-75C1E1C0DB57Q50534987-1DC7B07E-59CC-4B9B-B8DE-27BA4A3C8910Q50578303-8926ED29-03C2-453A-8A15-7EF61DF76B7EQ58781425-7E5B8B32-6B2A-4503-9E37-34EA9DE4B095
P2860
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@ast
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@en
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@nl
type
label
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@ast
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@en
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@nl
prefLabel
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@ast
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@en
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@nl
P2093
P2860
P3181
P1433
P1476
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model
@en
P2093
Jane C Naviaux
Laura L Dugan
Michael A Schuchbauer
Mihael Rogac
Qingbo Tang
Robert K Naviaux
Susan B Powell
Tomohiro Nakayama
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0057380
P407
P577
2013-01-01T00:00:00Z